Phase 2 N=50 BKM120 For Triple Negative Breast Cancer
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Phase 2 N=24 Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: 3 Months Progression Free Survival. Probability That the Cancer Has Not Progressed at 3 Months Calculated With Kaplan Meier. — 15.8 perceent probability at 3 months
Phase 3 N=182 A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
Triple-Negative Breast Cancer
Primary: Percentage of Participants With Treatment-emergent Grade ≥3 Adverse Events (AEs) — 46.70 percentage of participants
Phase 2 N=101 Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Triple-negative Breast Cancer
Primary: Number of Participants With Pathological Complete Response — 26; 28 Participants
Phase 2 N=71 Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-free Survival (PFS) — 4.4 Months
Phase 2 N=147 Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: Number of Participants With Pathologic Response by HR-deficiency (HRD) Status — 9; 2; 10; 4 Participants
Phase 2 N=43 Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7 · Stage IB Breast Cancer AJCC v7
Primary: Number of Participants With Residual Disease — 24 Participants
Phase 2 N=86 Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Breast Cancer
Primary: Objective Response Rate — 3; 19; 4; 57 Participants
Phase 2 N=15 Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Breast Cancer
Primary: Phase II: The Number of Subjects Exhibiting Pathologic Complete Response to Neoadjuvant Treatment With Sunitinib/Paclitaxel/Carboplatin — 12 participants
Phase 2 N=40 Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Breast Cancer
Primary: Complete Response Rate — 2; 8 Participants
Phase 2 N=10 TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 1 Participants
Phase 2 N=35 Cabozantinib for Metastatic Triple Negative BrCa
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
Phase 2 N=72 Phase II Trial for Large ER-Negative Breast Cancers
Malignant Neoplasm of Female Breast
Primary: Overall Response Rate — 25; 21 Participants
Phase 2 N=30 Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Metastatic Triple Negative Breast Cancer
Primary: Overall Response Rate (ORR) in Patients Treated With CNP — 2; 11; 6; 8 Participants
Phase 2 N=16 Vaccination of Triple Negative Breast Cancer Patients
Triple Negative Breast Cancer · Breast Neoplasms
Primary: Safety and Tolerability Adverse Events — 8; 81 Total events
Phase 3 N=333 A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
Triple-negative Breast Cancer
Primary: Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population — 69; 95 Number of…
Phase 2 N=60 Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
Breast Cancer
Primary: Pathological Complete Response Rates at Surgery — 16; 2 participants
Phase 2 N=37 Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Estrogen Receptor Negative · HER2/Neu Negative · Invasive Breast Carcinoma
Primary: Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6…
Phase 2 N=37 L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
Metastatic Triple Negative Breast Cancer
Primary: Asses the Maximum Tolerated Dose (MTD) of L-NMMA When Combined With Docetaxel/Amlodipine in the Treatment of Refractory Locally Advanced or Metastatic TNBC Patients…
Phase 2 N=173 Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer
Breast Neoplasm
Primary: Best Overall Response (BOR) — 20.0; 10.3 percentage of participants — p=0.1109
Phase 2 N=22 NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Breast Cancer · Triple Negative Breast Cancer
Primary: Tumor Response — 22 Participants
Phase 2 N=10 LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
Triple Negative Breast Cancer
Primary: Efficacy (Objective Response Rate) — 3 Participants
Phase 2 N=68 Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
Breast Neoplasms
Primary: Pathologic Complete Response (pCR) — 25 Participants
Phase 2 N=21 Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Phase 2 N=41 Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Breast Cancer
Primary: Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat…
Phase 2 N=135 PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Breast Cancer
Primary: Two-year Disease Free Survival — 54.2; 64.1 percentage of participants
Phase 2 N=50 Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Breast Cancer · Ductal Carcinoma · Invasive Breast Carcinoma
Primary: Phase I: Maximum Tolerated Dose (MTD) / Recommended Phase II Dose (RP2D) — 100 million plaque forming units per mL
Phase 3 N=651 A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Triple-Negative Breast Cancer
Primary: Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1…
Phase 2 N=151 A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response (pCR) in Breast and Axilla as Defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer Staging…